Developing regenerative medicine and their superselective administration protocols
Almost a decade of research on regenerative medicine and its applications in the treatment of auto-immune and incurable chronic disorders.
Here, we will help you find information about our work with stem cells and therapeutic applications
First of all, we thank you for taking the time to look at our website. If you're a patient, researcher, doctor or just another curious human being trying to get more information on our stem cell treatments, we are here to help..Read more
Introducing our group of researchers and clinicians who work tirelessly behind the scenes.
Here's to the founders and to all who have contributed in the development of the very methods of isolating the perfect cell lines and developing the superselective administration routes that have helped many patients to date.Read more
For an appointment with the PI, click here.
The application for studying the benefits of allogeneic human umbilical Cord derived mesenchymal stem cells in Multiple Sclerosis patients, has been granted...Scientific advisoryGenesis Institute of Cellular Medicine
Upcoming & ongoing comprehensive stem cell clinical trials
An open-label, non-randomized, phase I/II study of allogeneic human umbilical cord tissue-derived mesenchymal stem cells (UC-MSC) and liberation therapy (when associated with chronic cerebrovascular venous insufficiency) in patients with relapsing remitting multiple sclerosis (RRMS).
An open-label, non-randomized, phase I/II study of autologous bone marrow-derived mononuclear fraction of stem cells (BM-MNC) and liberation therapy (when associated with chronic cerebrovascular venous insufficiency) in patients with relapsing remitting multiple sclerosis (RRMS).
A study to rebuild baseline and current patient data for comparison with data collected in scheduled followups to be conducted and sponsored by Genesis for the establishment of subjective end points to gauge efficacy. The follow-up study application awaits IECP review and approval.